BioVie (BIVI) investor relations material

Company overview and business model

• Clinical-stage company focused on developing drug therapies for neurological, neurodegenerative disorders, and advanced liver disease.

• Lead programs include bezisterim (NE3107) for Alzheimer's, Parkinson's, and Long COVID, and BIV201 (terlipressin) for liver cirrhosis complications.

• Bezisterim targets neuroinflammation and insulin resistance, with ongoing Phase 2b and Phase 3 trials in multiple indications.

• BIV201 is a novel liquid formulation of terlipressin, targeting ascites in liver cirrhosis, with FDA Fast Track and Orphan Drug designations.

Financial performance and metrics

• Net loss for the year ended June 30, 2025 was $17.5 million, down from $32.1 million in the prior year, primarily due to reduced R&D expenses.

• As of March 31, 2026, cash and cash equivalents were $13.1 million, with working capital of $15.2 million and accumulated deficit of $368.6 million.

• No revenues have been generated to date; the company remains in the pre-revenue stage and expects continued operating losses.

• R&D expenses for the nine months ended March 31, 2026 were $10.4 million, mainly for clinical studies in Parkinson's and Long COVID.

Use of proceeds and capital allocation

• Estimated net proceeds from the offering are $70.0 million, assuming full sale at $1.33 per share.

• Proceeds will be used for working capital and general corporate purposes, including capital expenditures, R&D, and potential acquisitions.

• Management has broad discretion over the use of proceeds, which may not yield a significant return.